DREAM5: An open ‐label, randomized, cross‐over study to evaluate the safety and efficacy of day and night closed‐loop control using the MD‐Logic automated insulin delivery system compared to sensor augmented pump therapy in patients with type 1 diabetes at home

ConclusionsThe MD ‐Logic system was safe and associated with better glycemic control over SAP therapy for day and night use. The lack of remote monitoring did not lead to safety signals in adapting basal rates as well as in administration of automated bolus corrections.This article is protected by copyright. All rights reserved.

Source: Diabetes, Obesity and Metabolism - November 26, 2018 Category: Endocrinology Authors: Torben Biester, Judith Nir, Kerstin Remus, Alon Farfel, Ido Muller, Sarah Biester, Eran Atlas, Klemen Dovc, Natasa Bratina, Olga Kordonouri, Tadej Battelino, Moshe Philip, Thomas Danne, Revital Nimri Tags: ORIGINAL ARTICLE Source Type: research